First Published, Prospective, International, Observational Study of a NOAC for the Treatment and Secondary Prevention of VTE

XALIA: First Published, Prospective, International, Observational Study with a NOAC (Xarelto®) in DVT DVT
Deep vein thrombosis (= DVT). A blood clot in a deep vein, usually resulting from damage to the vein or blood flow slowing down or stopping. Usually DVTs are found in the leg, but can also be in the arm. Distal DVTs are found in deep veins of the calf, and are the most common type of DVT. Proximal DVTs are found in the legs above the calf muscle up to the waist.
1

Objective

  • Collect Real World data in patients with acute DVT treated with Xarelto or standard anticoagulation therapya,1

Study design

  • A large, multicentre, prospective, non-interventional study to evaluate the safety and efficacy of Xarelto in the Real World1
  • Patients were enrolled from June 2012 to March 2014 from 19 countries in Europe, plus Canada and Israel1

Population

5,142 adults with acute DVT and an indication to receive anticoagulation therapy for at least 3 months, who were treated with Xarelto or standard anticoagulation therapya,1

Key patient characteristics of Xarelto patients are consistent with EINSTEIN DVT2

Key patient characteristics of Xarelto patients are consistent with EINSTEIN DVT

DVT, deep vein thrombosis thrombosis
Formation of a clot inside a blood vessel.
. CrCl, creatinine clearance. VTE VTE
Venous thromboembolism (= VTE). A disease process beginning with a blood clot occurring within the venous system, including deep vein thrombosis and pulmonary embolism.
, venous thromboembolism. aInitial treatment with unfractionated heparin, low-molecular-weight heparin or fondaparinux; usually overlapping with and followed by a vitamin K antagonist.